Medication nonadherence in systemic lupus erythematosus is highest among younger adults facing access and scheduling barriers.

Employer healthcare costs are projected to increase by 11% next year due to rising hospital charges and prescription drug costs.

Adding cognitive behavioral therapy to a patient-centered opioid taper does not improve taper success but may reduce withdrawal symptoms.

Baseline functional impairment scores can independently predict difficult-to-manage axial spondyloarthritis at early follow-up.

Patients with rheumatic disease who use prescription opioids often experience disruptions in pain management during care transitions.

Buprenorphine dispensing rates and long-term initiation and retention remained consistently higher in rural than in urban US counties.

The FDA authorized the Aletta device, marking the first standalone robotic system cleared for autonomous blood draws in patients.

Severe gastrointestinal involvement is more frequent among patients with anti-NXP2 antibody-positive dermatomyositis than other antibody subgroups.

Rituximab is associatied with numerically higher remission rates in lupus membranous nephritis, although 12-month renal response rates did not differ significantly across immunosuppressive strategies.

For patients with PsA or axSpA, continuation of b/tsDMARD therapy varies depending on their countries' socioeconomic status.

Biologic therapy may alter the gut microbiome in patients with autoimmune arthritis, with specific microbial patterns linked to treatment response.

Emergency diagnosis of nonneoplastic conditions is associated with worse clinical outcomes, including increased mortality.